These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 33637618)

  • 41. The vascularization process after intravitreal ranibizumab injections for aggressive posterior retinopathy of prematurity.
    Sukgen EA; Koçluk Y
    Arq Bras Oftalmol; 2017; 80(1):30-34. PubMed ID: 28380099
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Characteristics of 'sawtooth shunt' following anti-vascular endothelial growth factor for aggressive posterior retinopathy of prematurity.
    Padhi TR; Das T; Kaur P; Sutar S; Khalsa A; Modi R; Ali H; Pradhan L; Jalali S
    Int Ophthalmol; 2020 Apr; 40(4):1007-1015. PubMed ID: 31925658
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Low-dose ranibizumab as primary treatment of posterior type I retinopathy of prematurity.
    Ells AL; Wesolosky JD; Ingram AD; Mitchell PC; Platt AS
    Can J Ophthalmol; 2017 Oct; 52(5):468-474. PubMed ID: 28985806
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Low-dose ranibizumab administration in retinopathy of prematurity.
    Tök L; Seyrek L; Yalçın Tök Ö
    Int Ophthalmol; 2022 May; 42(5):1545-1552. PubMed ID: 34993841
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Outcomes after Intravitreal Bevacizumab versus Laser Photocoagulation for Retinopathy of Prematurity: A 5-Year Retrospective Analysis.
    Hwang CK; Hubbard GB; Hutchinson AK; Lambert SR
    Ophthalmology; 2015 May; 122(5):1008-15. PubMed ID: 25687024
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Comparison of the Efficacy Between Intravitreal Aflibercept and Laser Photocoagulation in the Treatment of Retinopathy of Prematurity.
    Ekinci DY; Çelik K
    J Pediatr Ophthalmol Strabismus; 2020 Jan; 57(1):54-60. PubMed ID: 31972042
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Comparison of Bevacizumab and Ranibizumab in the Treatment of Type 1 Retinopathy of Prematurity Affecting Zone 1.
    Kimyon S; Mete A
    Ophthalmologica; 2018; 240(2):99-105. PubMed ID: 29920490
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Comparison of OCT angiography in children with a history of intravitreal injection of ranibizumab versus laser photocoagulation for retinopathy of prematurity.
    Zhao J; Wu Z; Lam W; Yang M; Chen L; Zheng L; Zhang F; Zeng J; Wang J; Zhang G
    Br J Ophthalmol; 2020 Nov; 104(11):1556-1560. PubMed ID: 32051137
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Refractive error outcomes after intravitreal ranibizumab for retinopathy of prematurity.
    Meng Q; Cheng Y; Wu X; Zhao D; Zhao M; Liang J
    Clin Exp Optom; 2020 Jul; 103(4):495-500. PubMed ID: 31802528
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Spectral-Domain OCT Analyses of Macular Changes After Ranibizumab Therapy for Type 1 Retinopathy of Prematurity.
    Erol MK; Coban DT; Özdemir Ö; Tunay ZÖ; Bilgin AB; Dogan B
    J Pediatr Ophthalmol Strabismus; 2015; 52(3):152-8. PubMed ID: 25859685
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Time Course of Retinopathy of Prematurity Regression and Reactivation After Treatment with Ranibizumab or Laser in the RAINBOW Trial.
    Fleck BW; Reynolds JD; Zhu Q; Lepore D; Marlow N; Stahl A; Li J; Weisberger A; Fielder AR;
    Ophthalmol Retina; 2022 Jul; 6(7):628-637. PubMed ID: 35202890
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Comparison of 12-month therapeutic effect of conbercept and ranibizumab for diabetic macular edema: a real-life clinical practice study.
    Xu Y; Rong A; Xu W; Niu Y; Wang Z
    BMC Ophthalmol; 2017 Aug; 17(1):158. PubMed ID: 28841827
    [TBL] [Abstract][Full Text] [Related]  

  • 53. [Effects of intravitreal pegaptanib or bevacizumab and laser in treatment of threshold retinopathy of prematurity in zone I and posterior zone II--four years results].
    Autrata R; Senková K; Holousová M; Krejcírová I; Dolezel Z; Borek I
    Cesk Slov Oftalmol; 2012 Feb; 68(1):29-36. PubMed ID: 22679695
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Intravitreal injection of bevacizumab for retinopathy of prematurity.
    Kuniyoshi K; Sugioka K; Sakuramoto H; Kusaka S; Wada N; Shimomura Y
    Jpn J Ophthalmol; 2014 May; 58(3):237-43. PubMed ID: 24566819
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Results of intravitreal ranibizumab treatment for retinopathy of prematurity in infants.
    Sukgen EA; Koçluk Y
    Cutan Ocul Toxicol; 2017 Dec; 36(4):356-361. PubMed ID: 28277877
    [TBL] [Abstract][Full Text] [Related]  

  • 56. SERUM VASCULAR ENDOTHELIAL GROWTH FACTOR AFTER BEVACIZUMAB OR RANIBIZUMAB TREATMENT FOR RETINOPATHY OF PREMATURITY.
    Wu WC; Shih CP; Lien R; Wang NK; Chen YP; Chao AN; Chen KJ; Chen TL; Hwang YS; Lai CC
    Retina; 2017 Apr; 37(4):694-701. PubMed ID: 27467377
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Comparison of bevacizumab, ranibizumab and aflibercept in retinopathy of prematurity treatment.
    Süren E; Özkaya D; Çetinkaya E; Kalaycı M; Yiğit K; Kücük MF; Erol MK
    Int Ophthalmol; 2022 Jun; 42(6):1905-1913. PubMed ID: 35094229
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Combined Vitrectomy and Anti-VEGF Treatment for Stage 4 Retinopathy of Prematurity With Extensive Neovascular Proliferation.
    Chandra P; Kumawat D; Agarwal D; Chawla R
    J Pediatr Ophthalmol Strabismus; 2020 Jan; 57(1):61-66. PubMed ID: 31972043
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Anti-vascular endothelial growth factor (VEGF) drugs for treatment of retinopathy of prematurity.
    Sankar MJ; Sankar J; Mehta M; Bhat V; Srinivasan R
    Cochrane Database Syst Rev; 2016; 2():CD009734. PubMed ID: 26932750
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Refractive outcomes following bevacizumab monotherapy compared with conventional laser treatment: a randomized clinical trial.
    Geloneck MM; Chuang AZ; Clark WL; Hunt MG; Norman AA; Packwood EA; Tawansy KA; Mintz-Hittner HA;
    JAMA Ophthalmol; 2014 Nov; 132(11):1327-33. PubMed ID: 25103848
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.